Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
NOVA Stock Chart & Stats
€48.80
€2.60(3.26%)
At close: 4:00 PM EST
€48.80
€2.60(3.26%)
Day’s Range― - ―
52-Week Range€36.10 - €90.40
Previous CloseN/A
Volume1.40K
Average Volume (3M)4.35K
Market Cap
€224.73B
Enterprise Value€257.56B
Total Cash (Recent Filing)€32.58B
Total Debt (Recent Filing)€101.21B
Price to Earnings (P/E)16.1
Beta0.95
Next Earnings
Feb 04, 2026EPS Estimate
0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.60
Shares Outstanding3,390,128,000
10 Day Avg. Volume5,948
30 Day Avg. Volume4,349
Financial Highlights & Ratios
PEG Ratio1.28
Price to Book (P/B)19.23
Price to Sales (P/S)9.50
P/FCF Ratio39.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€46.97Price Target Upside-3.75% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Strategy And AccessAnalyst highlights that renewed commercial execution combined with discounted introductory self-pay offers can improve affordability and accelerate patient uptake.
Market OpportunityA largely untapped obesity treatment market and patient demand for lower-cost oral options create a clear runway for significant volume growth as access expands.
Regulatory ApprovalFDA approval of oral semaglutide provides a first-mover advantage to capture patients who prefer oral dosing and could help regain incretin market share.
Bears Say
Adoption ConstraintsFasting and food restrictions associated with the Wegovy pill may limit patient uptake and hinder efforts to regain share against competing oral treatments.
Competitive PressureIntense competition from rival GLP-1 developers and new entrants is eroding market share and increases the challenge of defending commercial leadership.
Pricing And Margin PressureReduced GLP-1 pricing, pricing concessions and higher API costs for oral semaglutide are likely to pressure revenue growth and gross margins before volume gains appear.
Novo Nordisk News
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €36.10 and its highest was €90.40 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is €224.73B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Feb 04, 2026 which is in 19 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Nov 05, 2025. The company reported €0.596 earnings per share for the quarter, missing the consensus estimate of €0.658 by -€0.062.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Overvalued.
Does Novo Nordisk pay dividends?
Novo Nordisk does not currently pay dividends.
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.79.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.596 in its last earnings report, missing expectations of €0.658. Following the earnings report the stock price went down -0.357%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in DE:NOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€46.97 (-3.75% Downside)
€46.97 (-3.75% Downside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 87%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.73%
12-Months-Change
Fundamentals
Return on Equity
68.30%
Trailing 12-Months
Asset Growth
35.53%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NOVA Company Deck
NOVA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in sales and continued expansion in obesity care, supported by strategic acquisitions. However, significant challenges remain, including market share loss, restructuring efforts, and pricing pressures.View all DE:NOVA earnings summariesNOVA Stock 12 Month Forecast
Average Price Target
€46.97
▼(-3.75% Downside)
Technical Analysis
Options Prices
Currently, No data available
---